Drug intelligence / Profile preview

Forticolinn

Development stage: Unknown
Lead developer: INNventa Pharm
Modality: Peptides, Small Molecules
Administration: Oral

Overview

Forticolinn is a nutraceutical combination product developed by INNventa Pharm for the management of osteopenia and osteoporosis, as well as for accelerating recovery after bone fractures. The formulation consists of specific bioactive collagen peptides (FORTIBONE®) and calcium lactate. The bioactive collagen peptides are designed to stimulate the creation of both organic and inorganic bone matrix, thereby increasing bone mineral density and providing protection against fractures. It is particularly recommended for menopausal women as standalone therapy or as a supplement to existing osteoporosis treatments. The product is administered as an oral powder formulation in sachets, typically mixed with water or fruit juice.

Brand names: Forticolinn
Other names: Forticolinn®

Beyond the preview

Go deeper on Forticolinn.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forticolinn.

Explore the full profile